436 related articles for article (PubMed ID: 14699394)
1. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
2. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
3. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
6. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
17. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
20. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
[No Abstract] [Full Text] [Related]
[Next] [New Search]